ABEO Stock Analysis: Buy, Sell, or Hold?
ABEO - Abeona Therapeutics Inc. Common Stock
$6.32
-0.10 (-1.56%)
▼
5d:
+3.1%
30d:
-1.25%
90d:
+16.39%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
9d
Get Alerted When ABEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ABEO shows positive signals but monitor for confirmation. Market pricing in 1.5% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: ABEO shows positive signals but monitor for confirmation. Market pricing in 1.5% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$8.60
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.34
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABEO is currently trading at $6.32, which is considered fair relative to its 30-day fair value range of $5.85 to $6.89. The stock's valuation (Forward PE: 22.4) is in line with its historical norms (21.4). At these levels, the market is pricing in 1.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ABEO is in a strong uptrend. Immediate support is located at $5.83, while resistance sits at $6.62.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19.71 (+207.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABEO is in a strong uptrend. Immediate support is located at $5.83, while resistance sits at $6.62.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19.71 (+207.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.85 -
$6.89
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.3%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 207.1% below Wall St target ($19.71)
- NEUTRAL: Market pricing in 1.5% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$5.85 -
$6.89
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$5.83
Resistance Level
$6.62
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.39
Wall Street Target
$19.71
(+207.1%)
Revenue Growth (YoY)
-100.0%
Profit Margin
454.9%
Valuation Premium vs History
+1.5% premium
PE vs Historical
22.4 vs 21.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.5%
(market-implied from PE analysis)
1-Year Target
$6.52
(+2%)
2-Year Target
$6.61
(+3%)
3-Year Target
$6.71
(+5%)
3-Yr Target (if PE normalizes)
(PE: 22→21)
PE COMPRESSION
$6.42
(0%)
Earnings growth offset by PE compression
📈
Valuation based on Current Earnings
Trailing PE: 6.81 | Current EPS (TTM): $0.95
Bull Case
$3.56
(-45%)
Analyst growth -50.0%, PE expands to 7.5
Base Case
$3.23
(-50%)
Market implied -50.0%, PE stable at 6.8
Bear Case
$4.40
(-32%)
Severe decline -20.0%, PE contracts to 5.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 03, 2026 2:23 PM ET
Data refreshes hourly during market hours. Next update: 3:23 PM
Data refreshes hourly during market hours. Next update: 3:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 51 HOLD |
